OKYO Pharma Limited

Stage 4 · Declining · week 39

As of Oct 22, 2026, OKYO Pharma is in Stage 4, the downtrend phase, now in week 39 (since Jan 21, 2026). It closed at $1.47, 52.7% below its 52-week high and below its 200-day average, which is falling.

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. More about the company

$1.47

-4.22% today

$77.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is OKYO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S2 26w

S4 39w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 5w → S2 6w → S3 9w → S2 2w → S3 2w → S4 12w → S1 3w → S4 21w → S1 12w → S4 4w → S1 3w → S2 26w → S3 9w → S2 3w → S3 7w → S4 39w current

Total tracked: 165 weeks across 17 stage runs.

OKYO among Biotechnology308th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…308	OKYOOKYO Pharma Limited	Stage 4 · wk 39	30	+11.4%

vs 52W High

-52.7%

$1.29 lo$3.11 hi

52.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 39

1w13w26w

Week 39, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-11.0%

200 DMA: $1.65 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.07x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↗ ⇈

Short-term trend rising gently, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+11.4%

-5.2%

-7.5%

YTD

-34.1%

-36.6%

Scan Membership

Breakout Watch

Latest: 2025-03-13

4 appearances in last 60 days. First seen: 2023-03-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 39 · Vol 1.07x

2026-10-21S4

Wk 38 · Vol 3.74x

2026-10-20S4

Wk 38 · Vol 0.72x

2026-10-19S4

Wk 38 · Vol 0.35x

2026-10-16S4

Wk 38 · Vol 0.36x

2026-10-15S4

Wk 38 · Vol 0.69x

2026-10-14S4

Wk 37 · Vol 0.26x

2026-10-13S4

Wk 37 · Vol 0.29x

2026-10-12S4

Wk 37 · Vol 1.00x

2026-10-09S4

Wk 37 · Vol 1.68x

2026-10-08S4

Wk 37 · Vol 0.39x

2026-10-07S4

Wk 36 · Vol 0.47x

Moving averages & range

50 DMA

$1.45

200 DMA

$1.65

52W High

$3.11

52W Low

$1.29

5D Low

$1.37

Resistance levels (recent highs)

20d High

$1.53

60d High

$1.68

120d High

$1.75

250d High

$3.11

Next resistance

+4.4%

to 20d High

ROE

-263.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 6.3

OKYO Pharma: quick answers

What stage is OKYO Pharma in?

As of Oct 22, 2026, OKYO Pharma (OKYO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 21, 2026 and is in week 39. What the four stages mean

Is OKYO Pharma in an uptrend?

No. OKYO Pharma is in a Stage 4 downtrend. It trades 11.0% below its 200-day average, which is falling.

How far is OKYO Pharma from its 52-week high?

OKYO Pharma closed at $1.47 on Oct 22, 2026, 52.7% below its 52-week high of $3.11. Its 52-week low is $1.29.

How has OKYO Pharma performed over the past year?

As of Oct 22, 2026, OKYO Pharma is down 36.6% over the past year and down 34.1% so far in 2026.

Which sector and industry is OKYO Pharma in?

OKYO Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.